Hemofarm a.d.

Hemofarm a.d.

Native name	Хемофарм а.д.
Type	Public limited company
Industry	Pharmaceuticals
Founded	Vršac, Serbia (August 28, 1998 (1998-08-28)) First founded 1960
Headquarters	Vršac, Serbia
Key people	Ronald Seeliger (CEO)
Products	Pharmaceuticals, Prescription drugs
Revenue	€258.54 million (2013)
Net income	€26.22 million (2013)
Total assets	€312.20 million (2013)
Total equity	€193.80 million (2013)
Owner	STADA (100%)
Number of employees	2,484
Website	www.hemofarm.com

Hemofarm a.d. (full legal name: Hemofarm a.d. Farmaceutsko-hemijska industrija Vršac), a member of STADA Group, is a Serbian pharmaceutical company based in Vršac, Serbia. Founded in 1960, it is one of the largest domestic producer and exporter of medicines in Serbia. Hemofarm currently operates in more than 30 countries on 3 continents and has approximately 2,500 employees.

The core activity represents the manufacture of Rx and OTC medicines and products. Portfolio includes over 140 INNs, with about 280 forms and dosage forms.

Hemofarm was founded on June 1, 1960 in Vršac. In 2003 it opened the first factory for the production of medicine in the Republika Srpska. As of 2003 Hemofarm consisted of 21 subsidiaries, 12 of which were located in Serbia and Montenegro.

In 2004, the company acquired four other Serbian concerns, increasing its market share from 15% to 45% in the process. As of 2011, the company has a market share in terms of production and import of 30.7%.

Hemofarm was bought by the German STADA Arzneimittel pharmaceutical group for 480 million euros in 2006. Since August 9, 2009 Hemofarm has been a member of the German STADA Group.

Hemofarm’s R&D division was established in 1990, and it has been recognized by STADA as a competence center for development of new generic products not only for local and regional markets, but also for the whole STADA Group. An intensive development of products intended for registration and sale in the demanding European Union market started in 2007.